<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35456167</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2077-0383</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical medicine</Title>
          <ISOAbbreviation>J Clin Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2076</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm11082076</ELocationID>
        <Abstract>
          <AbstractText>Several novel treatments for chronic lymphocytic leukemia (CLL) have been recently approved based on the results of randomized clinical trials. However, real-world evidence (RWE) is also requested before and after drug authorization in order to confirm safety and to provide data for health technology assessments. We conducted a scoping review of the available RWE for targeted treatments of CLL, namely ibrutinib, acalabrutinib, idelalisib, and venetoclax, as well as for chemoimmunotherapy (CIT). In particular, we searched studies published since 1 January 2010 and reported outcomes of the above treatments based on health databases, registries, or phase IV studies, including named-patient programs. We included both full papers and abstracts of studies presented at major meetings. Overall, 110 studies were selected and analyzed: 28,880 patients were treated with ibrutinib, 1424 with idelalisib, 751 with venetoclax, 496 with acalabrutinib, and 14,896 with CIT. Reported discontinuation rates were higher than in clinical trials, while effectiveness could not be indirectly compared with clinical trials since a detailed case mix, including cytogenetic risk factors, was partially available and propensity scores rarely applied. RWE on CLL can help to set realistic outcomes with novel treatments, however, real-world studies should be fostered, and available data shared.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Marchetti</LastName>
            <ForeName>Monia</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-7615-0572</Identifier>
            <AffiliationInfo>
              <Affiliation>Haematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vitale</LastName>
            <ForeName>Candida</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-2592-8724</Identifier>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Città della Salute e della Scienza, University of Turin, 10126 Turin, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rigolin</LastName>
            <ForeName>Gian Matteo</ForeName>
            <Initials>GM</Initials>
            <Identifier Source="ORCID">0000-0002-8370-5190</Identifier>
            <AffiliationInfo>
              <Affiliation>Haematology Unit, Azienda Ospedaliera Universitaria di Ferrara, 44121 Ferrara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Haematology and Rheumatology Section, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vasile</LastName>
            <ForeName>Alessandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, University of Eastern Pedemont, 28100 Novara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Visentin</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-0271-7200</Identifier>
            <AffiliationInfo>
              <Affiliation>Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, 35128 Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scarfò</LastName>
            <ForeName>Lydia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Experimental Oncology, Department of Onco-Hematology, IRCCS San Raffaele Hospital, 20132 Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coscia</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-2123-7675</Identifier>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Città della Salute e della Scienza, University of Turin, 10126 Turin, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cuneo</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Haematology Unit, Azienda Ospedaliera Universitaria di Ferrara, 44121 Ferrara, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Haematology and Rheumatology Section, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Med</MedlineTA>
        <NlmUniqueID>101606588</NlmUniqueID>
        <ISSNLinking>2077-0383</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">acalabrutinib</Keyword>
        <Keyword MajorTopicYN="N">chronic lymphocytic leukemia</Keyword>
        <Keyword MajorTopicYN="N">ibrutinib</Keyword>
        <Keyword MajorTopicYN="N">idelalisib</Keyword>
        <Keyword MajorTopicYN="N">real-world evidence</Keyword>
        <Keyword MajorTopicYN="N">venetoclax</Keyword>
      </KeywordList>
      <CoiStatement>No conflict of interest to declare for A.V. M.M. received consultancy fees from Gilead srl and speaker fees from Amgen.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>1</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35456167</ArticleId>
        <ArticleId IdType="pmc">PMC9028394</ArticleId>
        <ArticleId IdType="doi">10.3390/jcm11082076</ArticleId>
        <ArticleId IdType="pii">jcm11082076</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Brugiatelli M., Bandini G., Barosi G., Lauria F., Liso V., Marchetti M., Mauro F.R., Meloni G., Zinzani P.L., Tura S., et al.  Management of chronic lymphocytic leukemia: Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Trans-plantation. Haematologica. 2006;91:1662–1673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17145603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mauro F.R., Bandini G., Barosi G., Billio A., Brugiatelli M., Cuneo A., Lauria F., Liso V., Marchetti M., Meloni G., et al.  SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leuk. Res. 2012;36:459–466. doi: 10.1016/j.leukres.2011.08.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.leukres.2011.08.013</ArticleId>
            <ArticleId IdType="pubmed">21885123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuneo A., Marchetti M., Barosi G., Billio A., Brugiatelli M., Ciolli S., Laurenti L., Mauro F.R., Molica S., Montillo M., et al.  Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leuk. Res. 2014;38:1269–1277. doi: 10.1016/j.leukres.2014.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.leukres.2014.06.017</ArticleId>
            <ArticleId IdType="pubmed">25063524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins R., Bowman L., Landray M., Peto R. The Magic of Randomization versus the Myth of Real-World Evidence. N. Engl. J. Med. 2020;382:674–678. doi: 10.1056/NEJMsb1901642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMsb1901642</ArticleId>
            <ArticleId IdType="pubmed">32053307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mwamburi M., Dalal H., Gala S. Trends in Research Using Observational Methodologies in Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review. Value Health. 2016;19:A760. doi: 10.1016/j.jval.2016.09.2361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jval.2016.09.2361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islam P., Mato A.R. Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. Curr. Hematol. Malign-Rep. 2020;15:254–260. doi: 10.1007/s11899-020-00584-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11899-020-00584-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno C., Montillo M., Panayiotidis P., Dimou M., Bloor A., Dupuis J., Schuh A., Norin S., Geisler C., Hillmen P., et al.  Ofatumumab in poor-prognosis chronic lymphocytic leukemia: A Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015;100:511–516. doi: 10.3324/haematol.2014.118158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2014.118158</ArticleId>
            <ArticleId IdType="pmc">PMC4380724</ArticleId>
            <ArticleId IdType="pubmed">25596264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitale C., Griggio V., Todaro M., Salvetti C., Boccadoro M., Coscia M. Magic pills: New oral drugs to treat chronic lym-phocytic leukemia. Expert Opin. Pharmacother. 2017;18:411–425. doi: 10.1080/14656566.2017.1293655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14656566.2017.1293655</ArticleId>
            <ArticleId IdType="pubmed">28234562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munir T., Brown J.R., O’Brien S., Barrientos J.C., Barr P.M., Reddy N.M., Coutre S., Tam C.S., Mulligan S.P., Jaeger U., et al.  Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am. J. Hematol. 2019;94:1353–1363. doi: 10.1002/ajh.25638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.25638</ArticleId>
            <ArticleId IdType="pmc">PMC6899718</ArticleId>
            <ArticleId IdType="pubmed">31512258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger J.A., Barr P.M., Robak T., Owen C., Ghia P., Tedeschi A., Bairey O., Hillmen P., Coutre S.E., Devereux S., et al.  Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787–798. doi: 10.1038/s41375-019-0602-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41375-019-0602-x</ArticleId>
            <ArticleId IdType="pmc">PMC7214263</ArticleId>
            <ArticleId IdType="pubmed">31628428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Novak J., Strugov V., Gill D., et al.  First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase 3 iLLUMINATE trial. Haematologica. 2022 doi: 10.3324/haematol.2021.279012. 
Epub ahead of print
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2021.279012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach J.A., Ruppert A.S., Heerema N.A., Zhao W., Booth A.M., Ding W., Bartlett N., Brander D.M., Barr P.M., Rogers K.A., et al.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N. Engl. J. Med. 2018;379:2517–2528. doi: 10.1056/NEJMoa1812836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1812836</ArticleId>
            <ArticleId IdType="pmc">PMC6325637</ArticleId>
            <ArticleId IdType="pubmed">30501481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanafelt T.D., Wang X.V., Kay N.E., Hanson C.A., O’Brien S., Barrientos J., Jelinek D.F., Braggio E., Leis J.F., Zhang C.C., et al.  Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2019;381:432–443. doi: 10.1056/NEJMoa1817073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1817073</ArticleId>
            <ArticleId IdType="pmc">PMC6908306</ArticleId>
            <ArticleId IdType="pubmed">31365801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitale C., Gibbons J.L., Ferrajoli A. Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib. OncoTargets Ther. 2021;14:5507–5519. doi: 10.2147/OTT.S303060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S303060</ArticleId>
            <ArticleId IdType="pmc">PMC8721287</ArticleId>
            <ArticleId IdType="pubmed">35002256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd J.C., Harrington B., O’brien S., Jones J.A., Schuh A., Devereux S., Chaves J., Wierda W.G., Awan F.T., Brown J.R., et al.  Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2016;374:323–332. doi: 10.1056/NEJMoa1509981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509981</ArticleId>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickerson T., Wiczer T., Waller A., Philippon J., Porter K., Haddad D., Guha A., Rogers K.A., Bhat S., Byrd J.C., et al.  Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919–1928. doi: 10.1182/blood.2019000840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2019000840</ArticleId>
            <ArticleId IdType="pmc">PMC6887116</ArticleId>
            <ArticleId IdType="pubmed">31582362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar P.S., Wiczer T., Rosen L., Pollauf A.J., Zheng A., Palettas M., Azali L., Bhat S.A., Byrd J.C., Rogers K., et al.  Evaluation of the incidence and risk factors associated with bleeding events in pa-tients receiving acalabrutinib therapy. Blood. 2021;138((Suppl. S1)):3729. doi: 10.1182/blood-2021-148719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2021-148719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts A.W., Davids M.S., Pagel J.M., Kahl B.S., Puvvada S.D., Gerecitano J.F., Kipps T.J., Anderson M.A., Brown J.R., Gressick L., et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2016;374:311–322. doi: 10.1056/NEJMoa1513257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1513257</ArticleId>
            <ArticleId IdType="pmc">PMC7107002</ArticleId>
            <ArticleId IdType="pubmed">26639348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kater A.P., Wu J.Q., Kipps T., Eichhorst B., Hillmen P., D’rozario J., Assouline S., Owen C., Robak T., de la Serna J., et al.  Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from the MURANO Phase III Study. J. Clin. Oncol. 2020;38:4042–4054. doi: 10.1200/JCO.20.00948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.20.00948</ArticleId>
            <ArticleId IdType="pmc">PMC7768340</ArticleId>
            <ArticleId IdType="pubmed">32986498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Sawaf O., Zhang C., Tandon M., Sinha A., Fink A.M., Robrecht S., Samoylova O., Liberati A.M., Pinilla-Ibarz J., Opat S., et al.  Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for pre-viously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1188–1200. doi: 10.1016/S1470-2045(20)30443-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30443-5</ArticleId>
            <ArticleId IdType="pubmed">32888452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C.-M., Chagorova T., DE LA Serna J., Dilhuydy M.-S., Illmer T., et al.  Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. N. Engl. J. Med. 2014;370:1101–1110. doi: 10.1056/NEJMoa1313984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1313984</ArticleId>
            <ArticleId IdType="pubmed">24401022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goede V., Fischer K., Engelke A., Schlag R., Lepretre S., Montero L.F.C., Montillo M., Fegan C., Asikanius E., Humphrey K., et al.  Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study. Leukemia. 2015;29:1602–1604. doi: 10.1038/leu.2015.14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2015.14</ArticleId>
            <ArticleId IdType="pubmed">25634683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharman J.P., Coutre S.E., Furman R.R., Cheson B.D., Pagel J.M., Hillmen P., Barrientos J.C., Zelenetz A.D., Kipps T.J., Flinn I.W., et al.  Final Results of a Randomized, Phase III Study of Rituximab with or without Idelalisib Followed by Open-Label Idelalisib in Patients with Relapsed Chronic Lymphocytic Leukemia. J. Clin. Oncol. 2019;37:1391–1402. doi: 10.1200/JCO.18.01460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.18.01460</ArticleId>
            <ArticleId IdType="pubmed">30995176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bird S.T., Tian F., Flowers N., Przepiorka D., Wang R., Jung T.-H., Kessler Z., Woods C., Kim B., Miller B.W., et al.  Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leuke-mia: A comparison of treatment outcomes in clinical trial participants vs Medicare beneficiaries. JAMA Oncol. 2020;6:248–254. doi: 10.1001/jamaoncol.2019.3994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.3994</ArticleId>
            <ArticleId IdType="pmc">PMC6990831</ArticleId>
            <ArticleId IdType="pubmed">31855259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eyre T.A., Osborne W.L., Gallop-Evans E., Ardeshna K.M., Kassam S., Sadullah S., Sidra G., Culligan D., Arumainathan A., Shankara P., et al.  Results of a multicenter UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. Br. J. Haematol. 2018;181:555–559. doi: 10.1111/bjh.14665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.14665</ArticleId>
            <ArticleId IdType="pubmed">28342183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schetlelig J., Chevallier P., van Gelder M., Hoek J., Hermine O., Chakraverty R., Browne P., Milpied N., Malagola M., Socié G., et al.  Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: A report from the EBMT chronic malignancies working party. Bone Marrow Transplant. 2021;56:605–613. doi: 10.1038/s41409-020-01069-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41409-020-01069-w</ArticleId>
            <ArticleId IdType="pmc">PMC8589680</ArticleId>
            <ArticleId IdType="pubmed">33004942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitale C., Salvetti C., Griggio V., Scamuffa M.C., Zamprogna G., Visentin A., Cassin R., Laurenti L., Murru R., Rivela P., et al.  Pre-existing and treatment-emergent autoimmune cytopenias in patients with chron-ic lymphocytic leukemia treated with targeted drugs. Blood. 2021;137:3507–3517. doi: 10.1182/blood.2020008201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2020008201</ArticleId>
            <ArticleId IdType="pubmed">33651883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pula B., Budziszewska B.K., Rybka J., Gil L., Subocz E., Długosz-Danecka M., Zawirska D., Waszczuk-Gajda A., Iskierka-Jażdżewska E., Kopacz A., et al.  Comparable efficacy of idelalisib plus rituximab and ibrutinib in relapsed/refractory chronic lymphocytic leukemia: A retrospective case matched study of the Polish Adult Leukemia Group (PALG) Anticancer. Res. 2018;38:3025–3030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29715135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zinzani P.L., Rambaldi A., Gaidano G., Girmenia C., Marchetti M., Pane F., Tura S., Barosi G. Infection control in patients candidate to treatment with ibrutinib or idelalisib in chronic lymphocytic leukemia: Recommendations from Italian Society of Hematology. Leuk. Res. 2019;81:88–94. doi: 10.1016/j.leukres.2019.04.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.leukres.2019.04.016</ArticleId>
            <ArticleId IdType="pubmed">31055248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuneo A., Follows G., Rigolin G.M., Piciocchi A., Tedeschi A., Trentin L., Perez A.M., Coscia M., Laurenti L., Musuraca G., et al.  GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum. Effi-cacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103:1209–1217. doi: 10.3324/haematol.2018.189837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2018.189837</ArticleId>
            <ArticleId IdType="pmc">PMC6029555</ArticleId>
            <ArticleId IdType="pubmed">29674504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuneo A., Mato A.R., Rigolin G.M., Piciocchi A., Gentile M., Laurenti L., Allan J.N., Pagel J.M., Brander D.M., Hill B.T., et al.  Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020;9:8468–8479. doi: 10.1002/cam4.3470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.3470</ArticleId>
            <ArticleId IdType="pmc">PMC7666748</ArticleId>
            <ArticleId IdType="pubmed">32969597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rigolin G.M., Cavazzini F., Piciocchi A., Arena V., Visentin A., Reda G., Zamprogna G., Cibien F., Vitagliano O., Coscia M., et al.  Efficacy of idelalisib and Rituximab in relapsed/refractory chronic lympho-cytic leukemia treated outside of clinical trials. A report of the GIMEMA Working Group. Hematol. Oncol. 2021;39:326–335. doi: 10.1002/hon.2861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hon.2861</ArticleId>
            <ArticleId IdType="pmc">PMC8451799</ArticleId>
            <ArticleId IdType="pubmed">33739461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatzikonstantinou T., Scarfo L., Demonsthenous C., Kotaskova J., Iacoboni G., Minga E., Chammou D., Karakatsoulis G., Albi E., Alcoceba M., et al.  Real-world evidence on therapeutic strategies and treatment-sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL. Blood. 2021;138:2635. doi: 10.1182/blood-2021-148738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2021-148738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarfo L., Albi E., Quaglia F.M., Marasca R., Sanna A., Murru R., Laurenti L., Gaidano G., Mannina D., Gentile M., et al.  An observational study on patients with relapsed/refractory chronic lymphocytic leu-kemia treated with venetoclax-based regimens outside clinical trials in Italy (GIMEMA CLL1920) Blood. 2021;138:3746. doi: 10.1182/blood-2021-148696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2021-148696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pacheco-Paez T., Conte C., Rousseau V., Chebane L., Ysebaert L., Levy V., Montastruc J., Despas F. Cardiovascular adverse drug reactions of ibrutinib, idelalisib, acalabrutinib, and venetoclax used in chronic lymphocytic leukemia: Systematic review, meta-analysis and Signal detection by dispropor-tionality analysis from VigiBase®. Fundament. Clin. Pharmacol. 2021;35((Suppl. S1)):38–39.</Citation>
        </Reference>
        <Reference>
          <Citation>Morabito F., Tripepi G., Del Poeta G., Mauro F.R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Bossio S., et al.  Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/refractory chronic lymphocytic leukemia cases. Eur. J. Haematol. 2021;106:493–499. doi: 10.1111/ejh.13573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejh.13573</ArticleId>
            <ArticleId IdType="pubmed">33378569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weymann D., Costa S., Regier D.A. Validation of a Cyclic Algorithm to Proxy Number of Lines of Systemic Cancer Therapy Using Administrative Data. JCO Clin. Cancer Inform. 2019;3:1–10. doi: 10.1200/CCI.19.00022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/CCI.19.00022</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
